Pharmafile Logo
Pharmafocus logo
Advanced Search

Entresto

Showing 13 posts of 13 posts found.

novartis_outside_1

Novartis’ Entresto narrowly misses Phase 3 goal in heart failure patients

September 2, 2019
Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma

New Phase 3 data for Novartis’ Entresto (sacubitril/valsartan) have been released, showing that the therapy narrowly missed its primary endpoint …

News
novartis_side_building

Novartis’ Entresto falls short at Phase 3 in heart failure with preserved ejection fraction

July 29, 2019
Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma

Novartis has been rocked by new Phase 3 data from a global trial into the efficacy of Entresto (sacubitril/valsartan), revealing …

News
novartis_window

Novartis’ Entresto tops enalapril in stabilised heart failure patients

November 13, 2018
Manufacturing and Production, Research and Development Entresto, Novartis, cardiovascular, enalapril, heart failure, pharma

Novartis has declared new findings for Entresto (sacubitril/valsartan) at the American Heart Association’s (AHA) scientific sessions, showing that the drug proved …

News
novartis_outside_1

Novartis’ Entresto helps preserve kidney function in chronic heart failure patients

April 16, 2018
Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma

Novartis has lifted the curtain on new data from a Phase 3 trial investigating the efficacy of Entresto (sacubitril/valsartan) in …

News
novartis_outside_1

Novartis rides out fiscal hardship to beat Q3 forecasts

October 25, 2016
Manufacturing and Production, Sales and Marketing Entresto, Gleevec, Novartis

Novartis has beaten its third-quarter sales projections, announcing that new product growth and cost cuts managed to carry the company …

News

Timely use of Novartis’ Entresto could prevent/delay over 28,000 US deaths a year – study

June 23, 2016
Research and Development, Sales and Marketing Entresto, JAMA Cardiology, Novartis, drug trial, research

A timely switch to Novartis’ (VTX: NOVN) heart failure drug Entresto (sacubitril/valsartan) in patients could prevent or delay more than …

News
entresto

NICE gives green light to Novartis’s heart drug Entresto

April 27, 2016
Research and Development, Sales and Marketing Entresto, NHS, NICE, Novartis, benefit, heart failure, patients

NICE has published final guidance recommending heart failure drug Entresto (sacubritil/valsartan). The drug, developed by Novartis, has performed well in …

News
novartis_window

Research shows Novartis’s Entresto reduces cardiovascular death and heart failure

April 4, 2016
Research and Development, Sales and Marketing Entresto, Novartis, Regeneron, Sanofi, cardiovascular, clinical trial, patent

Novartis has announced results from the PARADIGM-HF clinical trial that show that Entresto (sacubitril/valsartan) consistently demonstrated benefit among heart failure …

News
novartissunlight_copy

Novartis’s heart failure drug given final recommendation by NICE

March 21, 2016
Manufacturing and Production, Research and Development Entresto, NICE, Novartis, approval, draft, guidance, heart failure, heart failure drug

The National Institute for Health and Care Excellence (NICE) has issued its final guidance on Entresto (sacubritil/valsartan), a heart failure …

News
Novartis image

Novartis earns provisional NICE yes for Entresto

December 11, 2015
Sales and Marketing Entresto, NICE, Novartis, chronic heart failure, heart failure

NICE has indicated it is likely to recommend Entresto, a novel drug manufactured by Novartis, as a treatment option for …

News
EU flag

Novartis and Amgen drugs signed-off by European Commission

November 24, 2015
Manufacturing and Production Amgen, Entresto, European Commission, Novartis, blincyto

The European governing body, the European Commission, has approved the Novartis drug Entresto for heart failure and Amgen’s Blincyto for …

News

Novartis’ new heart failure medicine recommended for EU approval

September 25, 2015
Medical Communications, Research and Development Entresto, Novartis, eams, heart failure

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Novartis’s heart failure medication Entresto …

News
Entresto

Novartis heart failure drug available via EAMS

September 3, 2015
Sales and Marketing Early Access to Medicines Scheme, Entresto, LCZ696, MHRA, Novartis, eams, heart failure, sacubitril/valsartan

Novartis has won the investigational heart failure treatment LCZ696 (sacubitril valsartan) will be available in the UK under the Early …

News

Latest content

Novo Nordisk partners with UNICEF to prevent global childhood obesity

September 21, 2023

EC approves Menarini Group’s Orserdu for breast cancer treatment

September 21, 2023

Pharmanovia acquires CNS portfolio from Sanofi

September 20, 2023

Exscientia enters AI drug discovery collaboration with Merck KGaA

September 20, 2023

EC approves Pfizer’s Litfulo for adolescents and adults with alopecia

September 19, 2023